Brain PET-MRI Systems Market - By Phase (Clinical, Pre-clinical), Product Type (Traditional PET-MRI, Helium - Free PET-MRI), End-use (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes) - Global Forecast 2024 – 2032

Brain PET-MRI Systems Market Size

Brain PET-MRI Systems Market size was valued at around USD 353.7 million in 2023 and is estimated to grow at 5.9% CAGR from 2024 to 2032. Brain PET-MRI systems integrate positron emission tomography (PET) and magnetic resonance imaging (MRI) systems into a single platform. These systems enable simultaneous or sequential imaging of brain structure, function, and metabolism with high sensitivity and spatial resolution.
 

The rising incidence of neurological disorders is a significant driver for the market. For instance, according to the World Health Organization, neurological conditions had been a leading cause of illness and disability globally in 2021, affecting more than one in three individuals. This equated to over 3 billion people worldwide affected with various neurological conditions. This underscored the urgent need for advanced diagnostic technologies such as brain PET-MRI systems to enhance early detection and management of neurological disorders.
 

Furthermore, advancements in imaging technology, rising demand for non-invasive diagnostic tools, and growing focus on personalized medicine are the promoting factors advancing the growth of the market.
 

Brain PET-MRI Systems Market Trends

Advancements in imaging technology within the brain PET-MRI systems have revolutionized the landscape of neuroimaging, offering unprecedented insights into the structure and function of the brain. These systems combine the strengths of PET and MRI, integrating functional metabolic data with high-resolution anatomical images in a single comprehensive scan.

• PET-MRI systems merge PET's metabolic insights with MRI's detailed anatomical information. This integration delivers a holistic view of the brain's structure and function in a single scan, streamlining diagnostics and elevating accuracy.
   
• Rapid developments in radiotracer technology have broadened the scope of PET imaging. Tailored radiotracers, designed for specific neurotransmitter systems, receptors, or metabolic pathways, are revolutionizing imaging studies. These tracers pave the way for more precise diagnoses and personalized treatment plans.
   
• Moreover, cutting-edge image reconstruction algorithms, such as iterative and bayesian methods, are refining brain PET-MRI systems. They enhance image quality, diminish noise artifacts, and extract diagnostic insights more effectively from PET and MRI data. These enhancements not only heighten sensitivity and specificity in imaging but also bolster the clinical relevance and accuracy of neuroimaging studies, thus, driving market growth.
   

Brain PET-MRI Systems Market Analysis

Based on phase, the market is divided into clinical and pre-clinical. The clinical segment of the market is forecasted to reach USD 362.6 million by 2032.
 

• In clinical phase, brain PET-MRI systems play a crucial role in treatment planning and monitoring. They help physicians visualize disease progression, evaluate treatment responses, and adjust therapeutic strategies based on real-time imaging data.
   
• During the clinical phase, these systems are used for diagnosing a wide range of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, epilepsy, brain tumors, and neurodegenerative conditions. They provide comprehensive insights into both structural abnormalities and functional abnormalities within the brain.
   
• Further, brain PET-MRI systems undergo rigorous validation studies to assess their diagnostic accuracy, reliability, and safety in detecting and characterizing neurological conditions. These studies compare the performance of PET-MRI against existing imaging modalities and clinical standards, thus driving the market growth.
   

Based on product type, the brain PET-MRI systems market is segmented into traditional PET/MRI systems and helium-free PET/MRI system. The traditional PET/MRI systems segment accounted for USD 252.9 million in 2023.
 

• Traditional PET/MRI systems facilitate precise spatial registration of PET metabolic images with high-resolution MRI anatomical images. This alignment enhances the localization and characterization of abnormalities such as tumors, lesions, or metabolic changes within specific brain regions. The ability to overlay functional data onto detailed anatomical images improves diagnostic confidence and accuracy, thereby promoting the adoption of traditional PET/MRI systems.
   
• Additionally, traditional PET/MRI systems provide superior soft tissue contrast compared to CT, making it ideal for visualizing brain structures with high detail and clarity. This is crucial for identifying subtle abnormalities or small lesions that may not be well-defined on CT scans alone.
   
• Furthermore, traditional PET/MRI systems allow for multi-parametric imaging, combining functional, structural, and sometimes molecular imaging capabilities in a single session. This comprehensive approach facilitates a deeper understanding of disease mechanisms, treatment responses, and patient-specific variability, supporting personalized medicine approaches in neurology. Thus, propelling the growth of the market.
   

Based on end-use, the brain PET-MRI systems market is bifurcated into hospitals, diagnostic imaging centers, and academic and research institutes. The hospitals segment is forecasted to reach USD 284.2 million by 2032.
 

• Brain PET-MRI systems enable hospitals to explore personalized medicine approaches by correlating imaging findings with genetic, molecular, and clinical data. This integration supports the development of tailored treatment strategies based on individual patient profiles. As a result, Brain PET-MRI systems find extensive adoption across hospitals.
   
• Additionally, brain PET-MRI systems are also extensively used in evaluating neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease by detecting early changes in brain metabolism and structure. They aid in early diagnosis, disease staging, and tracking disease-modifying treatments.
   
• Further, hospitals leverage brain PET-MRI to assess the response to therapies in neurological disorders and brain tumors. By evaluating changes in metabolic activity and tumor size over time, clinicians can make informed decisions regarding treatment continuation, modification, or cessation. Thus, driving the revenue growth in hospitals segment.
   

The growth of the brain PET-MRI systems market in the U.S., projected to reach USD 214.5 million by 2032.
 

• The U.S. boasts robust research and development infrastructure supported by academic institutions, medical centers, and private sector investments. This ecosystem fosters collaborative research initiatives, clinical trials, and technological advancements aimed at improving diagnostic accuracy and patient outcomes.
   
• U.S.-based companies and research institutions are at the forefront of developing and advancing brain PET-MRI systems. They drive innovation in imaging technologies, including the integration of PET and MRI modalities, development of new radiotracers, and enhancement of image processing and analysis software.
   

The brain PET-MRI systems market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK regulatory framework ensures rigorous oversight and safety standards for medical devices, including PET-MRI systems. Clear regulatory pathways streamline the approval process for new technologies, facilitating market entry and commercialization for innovative imaging solutions.
   

Japan brain PET-MRI systems market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan invests in continuous education and training programs for healthcare professionals specializing in neuroimaging and medical diagnostics. Training initiatives enhance proficiency in interpreting PET-MRI images, optimizing scan protocols, and integrating imaging findings into clinical decision-making.
   
• Japan has a robust healthcare infrastructure and a high demand for advanced medical imaging solutions. Hospitals and healthcare facilities prioritize investments in state-of-the-art brain PET-MRI systems to meet diagnostic needs, enhance patient care outcomes, and improve operational efficiency.
   

The brain PET-MRI systems market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia collaborates with leading international healthcare providers and technology firms to enhance healthcare delivery and infrastructure development. Partnerships facilitate knowledge transfer, training programs for healthcare professionals, and access to state-of-the-art medical technologies such brain PET-MRI systems.
   

Brain PET-MRI Systems Market Share

The brain PET-MRI systems sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Brain PET-MRI Systems Market Companies

Some of the eminent market participants operating in the brain PET-MRI systems industry include:

• Aspect Imaging Ltd.              
• Bruker Corporation
• Canon Inc.
• Cubresa Inc.
• Fonar Corporation
• GE HealthCare Technologies, Inc.
• Hitachi, Ltd.
• Koninklijke Philips N.V.
• Mediso Ltd.
• Neusoft Corporation.
• Siemens Healthineers AG
   

Brain PET-MRI Systems Industry News:

• In May 2024, GE HealthCare introduced the SIGNA MAGNUS, head-only MRI scanner aimed at advancing neuroscience research. It targets deeper insights into brain structure and function, focusing on psychiatric diseases and neurological disorders. The SIGNA MAGNUS represents a potential breakthrough in understanding and treating complex brain conditions.
   
• In May 2023, Cubresa installed the first BrainPET Insert System at Lawson Health Research Institute in partnership with the hospital’s research institute. This collaboration provided Cubresa with a prestigious research opportunity, validating the system's capabilities and bolstering its reputation in the competitive medical imaging market.
   

The brain PET-MRI systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Phase

• Clinical
• Pre-clinical

Market, By Product Type

• Traditional PET/MRI systems
• Helium-free PET/MRI systems

Market, By End-use

• Hospitals
• Diagnostic imaging centers
• Academic research institutes

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacifi 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa